エリスロポエチン製剤の市場規模、シェア、動向分析レポートタイプ別（生物製剤、バイオシミラー）製品別（エリスロポエチン、ダルベポエチン-アルファ）用途別（がん、腎臓病、神経）地域別、セグメント予測2023～2030年

エリスロポエチン製剤の市場成長・動向

Grand View Research, Inc.の新しいレポートによると、世界のエリスロポエチン製剤の市場規模は、2023年から2030年にかけて1.5%のCAGRで拡大し、78億米ドルに達すると予想されています、成長の遅れは、複数の生物製剤の特許切れ、バイオシミラーの承認と普及の増加、価格の下落に起因していると考えられます。

例えば、PanGen Biotech Inc.は、Erisa（PDA10）を開発しています。このエリスロポエチンのバイオシミラー医薬品は、貧血患者における安全性と有効性を確認するため、第3相臨床試験中です。

米国保健社会福祉省は、慢性腎臓病の疾患について患者さんや医師の意識を高めるため、「全米腎臓病教育プログラム」を実施しています。腎臓は、成人のエリスロポエチン合成の唯一の供給源です。CKDが進行すると、腎臓の質量が減少し、その結果、エリスロポエチンの産生が障害され、貧血が引き起こされます。そのため、患者や医師の間で、この病気や利用可能なEPO医薬品に関する認識が高まっており、市場を牽引すると予想されます。

アジア太平洋、アフリカ、中東における安価なEPO医薬品への需要の高まりは、エリスロポエチン製剤市場への新規参入の引き金となりました。そのため、一部の主なプレーヤーはバイオシミラーの開発・商業化に取り組んでいます。例えば、Novotech（Australia）Pty Limitedは、EPOバイオシミラーであるEfepoetin alfaを第3相試験中です。

EPO製剤の安全性に関する懸念は、貧血の代替治療法の開発を促しています。例えば、roxudustat（AstraZeneca）やdaprodustat（GSK）などのHIF-PH阻害剤は、日本、中国、韓国などで承認されています。2022年3月、Zydus Lifesciences Ltd.は、インド医薬品監督庁（DCGI）からOxemia（Desidustat）の承認を取得しました。本剤は、注射用エリスロポエチン刺激剤の代替品となります。オキセミアは、慢性腎臓病に伴う貧血に対するインド初の経口治療薬として、アンメットニーズを解決する製品になる可能性があります。これらの代替薬の承認は、市場の成長にマイナスの影響を及ぼすと予想されます。

エリスロポエチン製剤の市場レポートハイライト

• タイプ別では、生物学的製剤が2022年の市場で最大のシェアを占めています。これは、がん別貧血やCKD患者の治療にFDA認可のEPO生物製剤が利用できることに起因していると考えられます。
• 製品別では、エリスロポエチンセグメントが、承認製品数の多さとエリスロポエチンの処方率の高さにより、2022年のEPO医薬品市場を独占しました。
• 2022年のEPO薬市場は、腎臓疾患セグメントが支配的でした。CKDの有病率の高さとEPO薬の処方率の高さが、このセグメントの優位性の主な要因となっています。全米腎臓財団（NKF）別と、世界では全人口の10％が慢性腎臓病（CKD）に罹患しています。
• 2022年の世界市場は、承認の遅れやバイオシミラーの市場浸透率の低さなどの要因により、北米が支配的となりました。

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
  • 地域範囲
• 調査手法
• 情報調達
  • 購入したデータベース
  • GVRの内部データベース
  • 二次情報
  • 1次調査
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析（モデル1）
    • アプローチ1：コモディティフローアプローチ
• 調査の仮定
• 二次情報一覧
• 略語一覧
• 目的

第2章 エグゼクティブサマリー

• 市場のスナップショット
• セグメントのスナップショット
• 競合情勢のスナップショット

第3章 エリスロポエチン製剤市場の変数、動向、および範囲

• 市場系列の見通し
  • 親市場の見通し
• タイプの浸透と成長の見通しマッピング、2022
• 市場力学
  • 市場促進要因分析
    • 慢性疾患の発生率の増加
    • 赤血球生成刺激剤（ESA）の適応外使用
  • 市場抑制要因分析
    • ブランド医薬品の特許満了
• 市場分析ツール
  • 業界分析：ポーターの5つの力
    • 新規参入業者の脅威：中程度
    • 買い手の交渉力：普通
    • 競争企業間の敵対関係：高い
    • 代替品の脅威：高
    • 供給企業の交渉力：低い
  • 業界分析：ペステル
    • 政治と法律
    • 経済的
    • 技術的な
• パイプライン分析

第4章 エリスロポエチン製剤市場：セグメント分析、タイプ別、2018年から2030年（100万米ドル）

• エリスロポエチン製剤市場：タイプの変動分析
  • 生物製剤
  • バイオシミラー

第5章 エリスロポエチン製剤市場：セグメント分析、製品別、2018年から2030年（100万米ドル）

• エリスロポエチン製剤市場：製品変動分析
  • エリスロポエチン
  • ダルベポエチンアルファ

第6章 エリスロポエチン製剤市場：セグメント分析、アプリケーション別、2018年から2030年（100万米ドル）

• エリスロポエチン製剤市場：アプリケーションの変動分析
  • がん
  • 腎疾患
  • 神経学
  • その他

第7章 エリスロポエチン製剤市場：タイプ、製品、およびアプリケーション別の地域推定・動向分析

• 北米
  • SWOT分析
  • 米国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • カナダ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 欧州
  • SWOT分析：
  • ドイツ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 英国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • フランス
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • イタリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スペイン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • デンマーク
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スウェーデン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • ノルウェー
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• アジア太平洋地域
  • SWOT分析：
  • 日本
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 中国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • インド
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • オーストラリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組みと償還のシナリオ
  • タイ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組みと償還のシナリオ
  • 韓国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組みと償還のシナリオ
• ラテンアメリカ
  • SWOT分析：
  • ブラジル
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • メキシコ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アルゼンチン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 中東およびアフリカ（MEA）
  • SWOT分析：
  • 南アフリカ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • サウジアラビア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アラブ首長国連邦
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • クウェート
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ

第8章 競合情勢

• Recent Developments &Impact Analysis, by Key Market Participants
  • 新製品の発売
  • 合併と買収
  • ライセンシング契約
  • カンファレンスとキャンペーン
• Company Categorization
  • イノベーター
  • 市場のリーダー
• Vendor Landscape
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
• Public Companies
  • 主要企業の市場シェア分析、2022年
  • 会社の市況分析
  • ヒートマップ分析
  • 競合ダッシュボード分析
    • 市場の差別化要因
• Private Companies
  • 主要新興企業一覧
  • 地域ネットワークマップ
• 企業プロファイル
  • Johnson &Johnson Services, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Novartis AG
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Teva Pharmaceutical Industries Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Amgen, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • LG Chem
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Biocon
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Intas Pharmaceuticals Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Sun Pharmaceutical Industries Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Dr. Reddy's Laboratories Ltd
    • 会社概要
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Erythropoietin Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 6 Global Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 7 Global Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 8 North America Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 10 North America Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 11 North America Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 12 U.S. Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 13 U.S. Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 14 U.S. Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 15 Canada Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 16 Canada Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 17 Canada Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 18 Europe Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 19 Europe Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 20 Europe Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 21 Europe Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 22 Germany Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 23 Germany Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 24 Germany Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 25 U.K. Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 26 U.K. Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 27 U.K. Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 28 France Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 29 France Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 30 France Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 31 Italy Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 32 Italy Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 33 Italy Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 34 Spain Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 35 Spain Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 36 Spain Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 37 Denmark Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 38 Denmark Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 39 Denmark Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 40 Sweden Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 41 Sweden Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 42 Sweden Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 43 Norway Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 44 Norway Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 45 Norway Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 50 Japan Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 51 Japan Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 52 Japan Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 53 China Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 54 China Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 55 China Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 56 India Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 57 India Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 58 India Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 59 South Korea Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 60 South Korea Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 61 South Korea Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 62 Australia Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 63 Australia Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 64 Australia Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 65 Thailand Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 66 Thailand Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 67 Thailand Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 68 Latin America Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 69 Latin America Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 70 Latin America Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 71 Latin America Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 72 Brazil Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 73 Brazil Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 74 Brazil Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 75 Mexico Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 76 Mexico Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 77 Mexico Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 78 Argentina Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 79 Argentina Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 80 Argentina Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 85 Saudi Arabia Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 88 South Africa Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 89 South Africa Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 90 South Africa Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 91 UAE Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 92 UAE Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 93 UAE Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 94 Kuwait Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
• Table 95 Kuwait Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
• Table 96 Kuwait Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Erythropoietin drugs market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value - chain - based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (By type, by product, and by application)
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Penetration & growth prospect mapping for type, 2022
• Fig. 13 Market driver relevance analysis (Current & future impact)
• Fig. 14 Market restraint relevance analysis (Current & future impact)
• Fig. 15 Erythropoietin drugs market: Type outlook and key takeaways
• Fig. 16 Erythropoietin drugs market: Type movement analysis
• Fig. 17 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Erythropoietin drugs market: Product outlook and key takeaways
• Fig. 20 Erythropoietin drugs market: Product movement analysis
• Fig. 21 Erythropoietin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Darbepoetin - alfa market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Erythropoietin drugs market: Application outlook and key takeaways
• Fig. 24 Erythropoietin drugs market: Application movement analysis
• Fig. 25 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Renal diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Regional Marketplace: Key Takeaways
• Fig. 30 North America: SWOT analysis
• Fig. 31 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 32 U.S. Key Country Dynamics
• Fig. 33 U.S. Target Disease Prevalence
• Fig. 34 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Canada Key Country Dynamics
• Fig. 36 Canada Target Disease Prevalence
• Fig. 37 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Europe: SWOT analysis
• Fig. 39 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Germany Key Country Dynamics
• Fig. 41 Germany Target Disease Prevalence
• Fig. 42 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 43 U.K. Key Country Dynamics
• Fig. 44 U.K. Target Disease Prevalence
• Fig. 45 U.K. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 France Key Country Dynamics
• Fig. 47 France Target Disease Prevalence
• Fig. 48 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Italy Key Country Dynamics
• Fig. 50 Italy Target Disease Prevalence
• Fig. 51 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Spain Key Country Dynamics
• Fig. 53 Spain Target Disease Prevalence
• Fig. 54 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Denmark Key Country Dynamics
• Fig. 56 Denmark Target Disease Prevalence
• Fig. 57 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Sweden Key Country Dynamics
• Fig. 59 Sweden Target Disease Prevalence
• Fig. 60 Sweden Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Norway Key Country Dynamics
• Fig. 62 Norway Target Disease Prevalence
• Fig. 63 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Rest of Europe Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Asia Pacific: SWOT Analysis
• Fig. 66 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Japan Key Country Dynamics
• Fig. 68 Japan Target Disease Prevalence
• Fig. 69 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 70 China Key Country Dynamics
• Fig. 71 China Target Disease Prevalence
• Fig. 72 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 73 India Key Country Dynamics
• Fig. 74 India Target Disease Prevalence
• Fig. 75 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Australia Key Country Dynamics
• Fig. 77 Australia Target Disease Prevalence
• Fig. 78 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 79 South Korea Key Country Dynamics
• Fig. 80 South Korea Target Disease Prevalence
• Fig. 81 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Thailand Key Country Dynamics
• Fig. 83 Thailand Target Disease Prevalence
• Fig. 84 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Rest of APAC Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Latin America (LATAM): SWOT Analysis
• Fig. 87 Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Brazil Key Country Dynamics
• Fig. 89 Brazil Target Disease Prevalence
• Fig. 90 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Mexico Key Country Dynamics
• Fig. 92 Mexico Target Disease Prevalence
• Fig. 93 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Argentina Key Country Dynamics
• Fig. 95 Argentina Target Disease Prevalence
• Fig. 96 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Rest of LATAM Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Middle East & Africa (MEA): SWOT Analysis
• Fig. 99 Middle East & Africa (MEA) Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 100 South Africa Key Country Dynamics
• Fig. 101 Target Disease Prevalence
• Fig. 102 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Saudi Arabia Key country dynamics
• Fig. 104 Saudi Arabia Target Disease Prevalence
• Fig. 105 Saudi Arabia Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 UAE Key Country Dynamics
• Fig. 107 UAE Target Disease Prevalence
• Fig. 108 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 109 Kuwait Key Country Dynamics
• Fig. 110 Kuwait Target Disease Prevalence
• Fig. 111 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 112 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 113 Heat Map Analysis
• Fig. 114 Strategic Framework

Erythropoietin Drugs Market Growth & Trends:

The global erythropoietin drugs market size is expected to reach USD 7.8 billion expanding at a CAGR of 1.5% from 2023 to 2030, according to a new report by Grand View Research, Inc., The slow growth can be attributed to the patent expiry of multiple biologics, increasing approval and penetration of biosimilars, and declining prices. For instance, PanGen Biotech Inc. is developing Erisa (PDA10). This erythropoietin biosimilar drug is under phase 3 clinical trial to check the safety and efficacy of the drug in patients with anemia.

The U.S. Department of Health and Human Services runs the National Kidney Disease Education Program to raise awareness about chronic kidney disease conditions among patients and physicians. The kidney is the sole source of erythropoietin synthesis in adults. In progressive CKD, the kidney mass decreases, which results in the impairment of erythropoietin production, thereby causing anemia. Thus, the rising awareness about the disease and its available EPO medicines among patients and physicians is anticipated to drive the market.

Increasing demand for cheaper EPO drugs in Asia Pacific, Africa, and the Middle East has triggered the entry of new players in the erythropoietin drugs market. Thus, some of the key players are engaged in the development and commercialization of biosimilars. For instance, Novotech (Australia) Pty Limited has an EPO biosimilar, Efepoetin alfa in phase 3 trials.

Safety concerns with EPO agents have encouraged the development of alternative treatments for anemia. For instance, HIF-PH inhibitors such as roxudustat (AstraZeneca) and daprodustat (GSK) have been approved in Japan, China, and South Korea amongst others. In March 2022, Zydus Lifesciences Ltd. received approval for Oxemia (Desidustat) from the Drug Controller General of India (DCGI). It is an alternative to injectable erythropoietin-stimulating agents. Oxemia is a potential product, a first-of-its-kind oral treatment in India, for anemia associated with chronic kidney diseases, thereby solving unmet needs. The approval of these alternative drugs is expected to negatively impact market growth.

Erythropoietin Drugs Market Report Highlights:

• By type, the biologics segment accounted for the largest share of the market in 2022. This can be attributed to the availability of FDA-approved EPO biologics for the treatment of cancer-induced anemia and CKD patients.

• Based on product, the erythropoietin segment dominated the EPO drugs market in 2022 owing to the higher number of approved products and higher prescription rate of erythropoietin.

• The renal diseases segment dominated the EPO drugs market in 2022. The high prevalence of CKD and the high prescription rate of EPO drugs are major factors contributing to the dominance of this segment. According to the National Kidney Foundation (NKF), 10% of the total population is affected by chronic kidney disease (CKD) worldwide.

• North America dominated the global market in 2022 owing to factors such as late approval and lower penetration of biosimilars in the market

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Regional scope
  • 1.1.2 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.1.1 Approach 1: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Erythropoietin Drugs Market Variables, Trends, and Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent market outlook
• 3.2 Penetration and Growth Prospect Mapping for Type, 2022
• 3.3 Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Increasing incidence of chronic diseases
    • 3.3.1.2 Off-label use of Erythropoiesis stimulating agents (ESAs)
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 Patent expiration of branded drugs
• 3.4 Market Analysis Tools
  • 3.4.1 Industry Analysis: Porter's Five Forces
    • 3.4.1.1 Threat of new entrants: Moderate
    • 3.4.1.2 Bargaining power of buyers: Moderate
    • 3.4.1.3 Competitive rivalry: High
    • 3.4.1.4 Threat of substitutes: High
    • 3.4.1.5 Bargaining power of suppliers: Low
  • 3.4.2 Industry Analysis: PESTEL
    • 3.4.2.1 Political & Legal
    • 3.4.2.2 Economical
    • 3.4.2.3 Technological
• 3.5 Pipeline Analysis

Chapter 4 Erythropoietin Drugs Market: Segment Analysis, by Type, 2018 - 2030 (USD Million)

• 4.1 Erythropoietin Drugs Market: Type Movement Analysis
  • 4.1.1 Biologics
    • 4.1.1.1 Biologics Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 4.1.2 Biosimilars
    • 4.1.2.1 Biosimilars Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 5 Erythropoietin Drugs Market: Segment Analysis, by Product, 2018 - 2030 (USD Million)

• 5.1 Erythropoietin Drugs Market: Product Movement Analysis
  • 5.1.1 Erythropoietin
    • 5.1.1.1 Erythropoietin Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 5.1.2 Darbepoetin-alfa
    • 5.1.2.1 Darbepoetin Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)

Chapter 6 Erythropoietin Drugs Market: Segment Analysis, by Application, 2018 - 2030 (USD Million)

• 6.1 Erythropoietin Drugs Market: Application Movement Analysis
  • 6.1.1 Cancer
    • 6.1.1.1 Cancer Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)
  • 6.1.2 Renal Diseases
    • 6.1.2.1 Renal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 6.1.3 Neurology
    • 6.1.3.1 Neurology Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 6.1.4 Others
    • 6.1.4.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 7 Erythropoietin Drugs Market: Regional Estimates and Trend Analysis, by Type, Product, & Application

• 7.1 North America
  • 7.1.1 SWOT Analysis
    • 7.1.1.1 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.1.2 U.S.
    • 7.1.2.1 Key Country Dynamics
    • 7.1.2.2 Target Disease Prevalence
    • 7.1.2.3 Competitive Scenario
    • 7.1.2.4 Regulatory Framework
    • 7.1.2.5 Reimbursement Scenario
    • 7.1.2.6 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.1.3 Canada
    • 7.1.3.1 Key Country Dynamics
    • 7.1.3.2 Target Disease Prevalence
    • 7.1.3.3 Competitive Scenario
    • 7.1.3.4 Regulatory Framework
    • 7.1.3.5 Reimbursement Scenario
    • 7.1.3.6 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.2 Europe
  • 7.2.1 SWOT Analysis:
    • 7.2.1.1 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2 Germany
    • 7.2.2.1 Key Country Dynamics
    • 7.2.2.2 Target Disease Prevalence
    • 7.2.2.3 Competitive Scenario
    • 7.2.2.4 Regulatory Framework
    • 7.2.2.5 Reimbursement Scenario
    • 7.2.2.6 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3 UK
    • 7.2.3.1 Key Country Dynamics
    • 7.2.3.2 Target Disease Prevalence
    • 7.2.3.3 Competitive Scenario
    • 7.2.3.4 Regulatory Framework
    • 7.2.3.5 Reimbursement Scenario
    • 7.2.3.6 UK Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4 France
    • 7.2.4.1 Key Country Dynamics
    • 7.2.4.2 Target Disease Prevalence
    • 7.2.4.3 Competitive Scenario
    • 7.2.4.4 Regulatory Framework
    • 7.2.4.5 Reimbursement Scenario
    • 7.2.4.6 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.5 Italy
    • 7.2.5.1 Key Country Dynamics
    • 7.2.5.2 Target Disease Prevalence
    • 7.2.5.3 Competitive Scenario
    • 7.2.5.4 Regulatory Framework
    • 7.2.5.5 Reimbursement Scenario
    • 7.2.5.6 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.6 Spain
    • 7.2.6.1 Key Country Dynamics
    • 7.2.6.2 Target Disease Prevalence
    • 7.2.6.3 Competitive Scenario
    • 7.2.6.4 Regulatory Framework
    • 7.2.6.5 Reimbursement Scenario
    • 7.2.6.6 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.7 Denmark
    • 7.2.7.1 Key Country Dynamics
    • 7.2.7.2 Target Disease Prevalence
    • 7.2.7.3 Competitive Scenario
    • 7.2.7.4 Regulatory Framework
    • 7.2.7.5 Reimbursement Scenario
    • 7.2.7.6 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.8 Sweden
    • 7.2.8.1 Key Country Dynamics
    • 7.2.8.2 Target Disease Prevalence
    • 7.2.8.3 Competitive Scenario
    • 7.2.8.4 Regulatory Framework
    • 7.2.8.5 Reimbursement Scenario
    • 7.2.8.6 Sweden Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.9 Norway
    • 7.2.9.1 Key Country Dynamics
    • 7.2.9.2 Target Disease Prevalence
    • 7.2.9.3 Competitive Scenario
    • 7.2.9.4 Regulatory Framework
    • 7.2.9.5 Reimbursement Scenario
    • 7.2.9.6 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.9.7 Rest of Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3 Asia Pacific
  • 7.3.1 SWOT Analysis:
    • 7.3.1.1 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2 Japan
    • 7.3.2.1 Key Country Dynamics
    • 7.3.2.2 Target Disease Prevalence
    • 7.3.2.3 Competitive Scenario
    • 7.3.2.4 Regulatory Framework
    • 7.3.2.5 Reimbursement Scenario
    • 7.3.2.6 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3 China
    • 7.3.3.1 Key Country Dynamics
    • 7.3.3.2 Target Disease Prevalence
    • 7.3.3.3 Competitive Scenario
    • 7.3.3.4 Regulatory Framework
    • 7.3.3.5 Reimbursement Scenario
    • 7.3.3.6 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4 India
    • 7.3.4.1 Key Country Dynamics
    • 7.3.4.2 Target Disease Prevalence
    • 7.3.4.3 Competitive Scenario
    • 7.3.4.4 Regulatory Framework
    • 7.3.4.5 Reimbursement Scenario
    • 7.3.4.6 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5 Australia
    • 7.3.5.1 Key Country Dynamics
    • 7.3.5.2 Target Disease Prevalence
    • 7.3.5.3 Competitive Scenario
    • 7.3.5.4 Regulatory Framework & Reimbursement Scenario
    • 7.3.5.5 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6 Thailand
    • 7.3.6.1 Key Country Dynamics
    • 7.3.6.2 Target Disease Prevalence
    • 7.3.6.3 Competitive Scenario
    • 7.3.6.4 Regulatory Framework & Reimbursement Scenario
    • 7.3.6.5 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7 South Korea
    • 7.3.7.1 Key Country Dynamics
    • 7.3.7.2 Target Disease Prevalence
    • 7.3.7.3 Competitive Scenario
    • 7.3.7.4 Regulatory Framework & Reimbursement Scenario
    • 7.3.7.5 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7.6 Rest of Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4 Latin America
  • 7.4.1 SWOT Analysis:
    • 7.4.1.1 Latin America Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.2 Brazil
    • 7.4.2.1 Key Country Dynamics
    • 7.4.2.2 Target Disease Prevalence
    • 7.4.2.3 Competitive Scenario
    • 7.4.2.4 Regulatory Framework
    • 7.4.2.5 Reimbursement Scenario
    • 7.4.2.6 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3 Mexico
    • 7.4.3.1 Key Country Dynamics
    • 7.4.3.2 Target Disease Prevalence
    • 7.4.3.3 Competitive Scenario
    • 7.4.3.4 Regulatory Framework
    • 7.4.3.5 Reimbursement Scenario
    • 7.4.3.6 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4 Argentina
    • 7.4.4.1 Key Country Dynamics
    • 7.4.4.2 Target Disease Prevalence
    • 7.4.4.3 Competitive Scenario
    • 7.4.4.4 Regulatory Framework
    • 7.4.4.5 Reimbursement Scenario
    • 7.4.4.6 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4.7 Rest of Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5 Middle East & Africa (MEA)
  • 7.5.1 SWOT Analysis:
    • 7.5.1.1 Middle East & Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2 South Africa
    • 7.5.2.1 Key Country Dynamics
    • 7.5.2.2 Target Disease Prevalence
    • 7.5.2.3 Competitive Scenario
    • 7.5.2.4 Regulatory Framework
    • 7.5.2.5 Reimbursement Scenario
    • 7.5.2.6 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3 Saudi Arabia
    • 7.5.3.1 Key Country Dynamics
    • 7.5.3.2 Target Disease Prevalence
    • 7.5.3.3 Competitive Scenario
    • 7.5.3.4 Regulatory Framework
    • 7.5.3.5 Reimbursement Scenario
    • 7.5.3.6 Saudi Arabia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4 UAE
    • 7.5.4.1 Key Country Dynamics
    • 7.5.4.2 Target Disease Prevalence
    • 7.5.4.3 Competitive Scenario
    • 7.5.4.4 Regulatory Framework
    • 7.5.4.5 Reimbursement Scenario
    • 7.5.4.6 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5 Kuwait
    • 7.5.5.1 Key Country Dynamics
    • 7.5.5.2 Target Disease Prevalence
    • 7.5.5.3 Competitive Scenario
    • 7.5.5.4 Regulatory Framework
    • 7.5.5.5 Reimbursement Scenario
    • 7.5.5.6 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5.7 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

• 8.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 8.1.1 New Product Launch
  • 8.1.2 Merger and Acquisition
  • 8.1.3 Licensing Agreements
  • 8.1.4 Conferences and Campaigns
• 8.2 Company Categorization
  • 8.2.1 Innovators
  • 8.2.2 Market Leaders
• 8.3 Vendor Landscape
  • 8.3.1 List of Key Distributors and Channel Partners
  • 8.3.2 Key Customers
• 8.4 Public Companies
  • 8.4.1 Key Company Market Share Analysis, 2022
  • 8.4.2 Company Market Position Analysis
  • 8.4.3 Heat Map Analysis
  • 8.4.4 Competitive Dashboard Analysis
    • 8.4.4.1 Market Differentiators
• 8.5 Private Companies
  • 8.5.1 List of Key Emerging Companies
  • 8.5.2 Regional Network Map
• 8.6 Company Profiles
  • 8.6.1. Johnson & Johnson Services, Inc.
    • 8.6.1.1 Company Overview
    • 8.6.1.2 Financial Performance
    • 8.6.1.3 Product Benchmarking
    • 8.6.1.4 Strategic Initiatives
  • 8.6.2 Novartis AG
    • 8.6.2.1 Company Overview
    • 8.6.2.2 Financial Performance
    • 8.6.2.3 Product Benchmarking
    • 8.6.2.4 Strategic Initiatives
  • 8.6.3 Teva Pharmaceutical Industries Ltd.
    • 8.6.3.1 Company Overview
    • 8.6.3.2 Financial Performance
    • 8.6.3.3 Product Benchmarking
    • 8.6.3.4 Strategic Initiatives
  • 8.6.4 Amgen, Inc.
    • 8.6.4.1 Company Overview
    • 8.6.4.2 Financial Performance
    • 8.6.4.3 Product Benchmarking
    • 8.6.4.4 Strategic Initiatives
  • 8.6.5 F. Hoffmann-La Roche Ltd.
    • 8.6.5.1 Company Overview
    • 8.6.5.2 Financial Performance
    • 8.6.5.3 Product Benchmarking
    • 8.6.5.4 Strategic Initiatives
  • 8.6.6 LG Chem
    • 8.6.6.1 Company Overview
    • 8.6.6.2 Financial Performance
    • 8.6.6.3 Product Benchmarking
    • 8.6.6.4 Strategic Initiatives
  • 8.6.7 Biocon
    • 8.6.7.1 Company Overview
    • 8.6.7.2 Financial Performance
    • 8.6.7.3 Product Benchmarking
    • 8.6.7.4 Strategic Initiatives
  • 8.6.8 Intas Pharmaceuticals Ltd.
    • 8.6.8.1 Company Overview
    • 8.6.8.2 Financial Performance
    • 8.6.8.3 Product Benchmarking
    • 8.6.8.4 Strategic Initiatives
  • 8.6.9 Sun Pharmaceutical Industries Ltd.
    • 8.6.8.1 Company Overview
    • 8.6.9.2 Financial Performance
    • 8.6.9.3 Product Benchmarking
    • 8.6.9.4 Strategic Initiatives
  • 8.6.10 Dr. Reddy's Laboratories Ltd
    • 8.6.10.1 Company Overview
    • 8.6.10.2 Product Benchmarking
    • 8.6.10.3 Strategic Initiatives